Friday, January 21, 2011

A novel proprietary technology which stabilizes vaccines

Stabilitech has developed a novel proprietary technology which stabilizes vaccines, biopharmaceuticals and other biological products. Currently, to ensure potency, vaccines and biopharmaceuticals require storage and transport under strictly controlled temperatures in a cold chain. Stabilitech’s technology will enable long term stable storage of vaccines and other biological products over a wide range of temperatures. The technology has been successfully applied to live viral vaccines, inactivated viruses and sub-unit vaccines as well as to antibodies, peptides, enzymes, growth factors and other proteins. Stabilitech’s approach involves the addition of carefully selected excipients at optimized concentrations and ratios, followed by freeze drying. The excipients have all been previously used in clinical settings, and are relatively inexpensive and readily available.

No comments: